anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: group of inventions relates to medical equipment, specifically to pressure maintenance system (10) and electronic data medium. System (10) is configured to adjust parameters of flow of respiratory gas under pressure, supplied to subject (12). System comprises pressure generator (14) configured to generate a respiratory gas flow under pressure to be supplied to an individual&#39;s respiratory tract. System includes humidifier (16) configured to humidify the flow of respiratory gas under pressure. System has sensors (18) configured to generate output signals carrying information relating to parameters of the flow of pressurized breathing gas. System comprises user interface (20) configured to receive feedback information from a subject indicating a comfort level with respect to the flow of pressurized breathing gas. System includes physical computer processors (22) which, owing to computer-readable instructions, are configured to control a pressure generator and a humidifier for feeding a respiratory gas flow under pressure to a subject, in accordance with a preset therapeutic mode, based on the output signals. Processors are configured to receive feedback information input through a user interface. Processors are configured to perform automatic control of flow of respiratory gas under pressure to increase comfort level of the subject. Automatic adjustment is based on received feedback information and output signals and includes adjustment of pressure and/or humidifier generator. Due to computer-readable instructions, processors (22) are additionally configured to receive additional feedback information introduced through the user interface after automatic adjustment. Processors are configured to provide a subject with a hint through a user interface for manual adjustment of a pressure generator, a humidifier or an ambient environment based on additional feedback information. Electronic data medium contains computer-readable instructions stored in electronic form, which, when executing a computer program, cause physical computer processors (22) to function.EFFECT: technical result is user feedback through user interface on operating condition of system and ambient conditions.11 cl, 4 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new aspartyl protease inhibitor.  &lt;P&gt;SOLUTION: A new class of sulfonamides which are aspartyl protease inhibitors is provided. In one embodiment, a new class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features is provided. A pharmaceutical composition containing these compounds is also provided. The compound and the pharmaceutical composition are particularly sufficiently suitable for inhibiting HIV-1 and HIV-2 protease activities and consequently may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. A method for inhibiting the activity of HIV aspartyl protease using the compound and a method for screening compounds for anti-HIV activity are also provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That&#39;s why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.
The invention relates to a process of modification of the nitrogen oxides metabolism by means of modification of the micellar catalysis parameters of NO oxidation. According to the invention, the number of phases and/or the volume ratio of the phases and/or the coefficients of distribution of NO and O2 between the phases are modified. The number of phases is modified by using perfluorocarbons, haloid derivatives thereof and perfluoralkylamines with a high coefficient of distribution of NO and O2, which are used as a hydrophobic phase for micellar analysis. The invention also relates to compositions used to vary the output of nitrite, nitrate, nitrosothiols and other oxidation products, whereby said compositions include emulsions of perfluororganic compounds, catalysts and inhibitors of excessive nitrosation, reducers, free radical scavengers and nitrosation targets which modify the balance of the nitrosated biogeneous compounds. The inventive methods for acting on a patient&#39;s organism include using such compositions together with variations in temperature and moisture and with traditional drugs. Independent claims in this invention also relate to the use of the known blood replacement substances containing perfluorated compounds and of the steam bath or the sauna in order to accelerate NO oxidation.
In vitro and in vivo application of sub-atmospheric, negative pressure on growth factor starting material, such as whole blood, extracts growth factors from the platelet granules of the growth factor starting material in a non-destructive medium without activating the clotting process. The extracted growth factors are released into a growth factor composition containing blood plasma, extracellular fluid or interstitial fluid depending upon the type and location of the growth factor starting material. The growth factors have a weight of about 70-76 kDaltons and are applied in either a filtered or unfiltered state topically to the area of a surface wound to effect healing. The extracted growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient&#39;s own blood. In another method the growth factors are released from a whole blood source and freeze dried by lyophilization. Then at a later date, the freeze-dried product is reconstituted by normal saline for treatment of a patient&#39;s wound, for use in a surgical procedure, or for tissue regeneration.
FIELD: medicine, stomatology. SUBSTANCE: the present innovation deals with blockade of affected branches of trigeminal nerve (TN) in case of its neuralgia and neuropathy. One should carry out combined blockade of TN affected branches with 20%-GHBA solution with 2%-lidocaine hydrochloride solution in one and the same syringe. Moreover, at neuropathy/neuralgia of TN first branch one should inject 0.5-1.0 ml solution into area of supraorbital nerve exit. At neuralgia/neuropathy of TN second branch 2.0 ml solution should be injected: 1.5 ml into exit area of suborbital nerve out of analogous channel and 0.5 ml into exit area of superior posterior alveolar nerves in mandibular tuber&#39;s area, or, in severe cases, according to stem anesthesia of TN second branch it is necessary to inject 2.0 ml. At neuralgia/neuropathy of TN third branch 1.5 ml solution should be injected either into area of mandibular torus or exit area of peripheral branch out of mental opening, and, also, in severe cases, 2.0 ml according to stem anesthesia of TN third branch. Course consists of 7-10 daily blockades. The present method enables to decrease dosage of local anesthetic at no risk for developing respiratory stoppage and shorten terms for staying in hospital. EFFECT: higher efficiency of therapy. 2 ex, 2 tbl
Cells capable of at least, in part, complementing adenovirus E2A function of an adenovirus defective in E2A function. Such cells include a nucleic acid encoding adenovirus E2A or a functional part, derivative and/or analogue thereof, integrated into the cell&#39;s genome. The cell may have E2A nucleic acid derived from a temperature sensitive adenovirus. Methods for producing an adenovirus particle containing an adenovirus vector with a functional deletion of E2A are also disclosed. Such methods involve providing a cell with the functionally deleted adenovirus vector, culturing the cell, and harvesting viral particle. The functional deletion can comprise a deletion of nucleic acid encoding E2A. In such a method, the nucleic acid encoding adenovirus E2A in the cell&#39;s genome has no sequence overlap with the vector leading to replication competent adenovirus and/or to the formation of an adenovirus vector comprising E2A function. In the method, the adenovirus vector may further include a functional deletion of E1-region encoding nucleic acid. Methods for providing cells of an individual with a nucleic acid of interest, without risk of administering simultaneously a replication competent adenovirus vector, comprising administering the individual one of the previously described preparations are also disclosed.
The method assesses the effectiveness of compounds for treatment of conditions characterised by a deficiency in number or function of membrane bound receptors and may be concerned with assessing putative agents for treatment of cognitive dysfunction conditions, including Alzheimer&#39;s disease. In the method, cells transfected with appropriate DNA are grown beyond the usual level to approach or reach equilibrium; the growth medium is then removed and the test agent added. A control is carried out using only the vehicle in which the test agent is dissolved. The samples are then incubated for, preferably, 72 hours, and an assay for the receptor or receptor type of interest is carried out. Comparison of results between control and test sample indicate the likely usefulness of the test compound. In a preferred embodiment, Chinese Hamster Ovary (CHO) cells are transfected with DNA for the muscarinic acetylcholine receptor, and receptor number is assayed using a [&lt;SP&gt;3&lt;/SP&gt;H]-NMS and [&lt;SP&gt;3&lt;/SP&gt;H]-QNB binding assay.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for preparing an isosorbide composition having excellent stability.  &lt;P&gt;SOLUTION: A crude isosorbide composition is prepared by dehydrating sorbitol using a dehydration catalyst comprising isosorbide as a main ingredient and containing impurities. The crude isosorbide composition is distilled in the absence of a solvent to obtain a distillate. The distillate is treated to be decolored using activated carbon to obtain a decolored product. The decolored product is heated in the absence of a solvent and the isosorbide composition reduced in the content of 1, 4-sorbitan is obtained by chemically reacting 1, 4-sorbitan which is an impurity having higher boiling point than that of isosorbide among impurities distilled during the distillation.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a manufacturing method of a vesicle by which a high encapsulating ratio of a desired substance can be attained while controlling desired physical properties such as particle size.  &lt;P&gt;SOLUTION: W/O emulsion is produced by blending an oil phase containing an emulsifier with an aqueous solution containing the substance to be encapsulated in a dissolved state or a suspended state. Then the W/O emulsion is cooled to temperature at which the aqueous solution therein becomes frozen particles while the oil phase maintains a liquid state and the oil phase is removed. Then the oil phase containing a vesicle constituting lipid is added to the frozen particles and obtained mixture is agitated to substitute the vesicle constituting lipid for the emulsifier at a frozen particle surface. Further an outside aqueous phase is added to the frozen particle the surface of which is covered with a lipid membrane to hydrate the outside aqueous phase and the lipid membrane.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new pharmaceutical composition in which an azole-based antimicrobial medicine such as itraconazole, sapeconazole, ketoconazole or fluconazole has good solubility and bioavailability.  &lt;P&gt;SOLUTION: The new composition is a granular medicine which comprise a core and a medicine emulsion layer, and optionally, a protective layer. The medicine emulsion layer contains the azole antimicrobial medicine, an emulsifier, a binder, and an absorbent aid. The preferred emulsifier is vitamin E polyethylene glycol succinate. The preferred binder is hydroxypropyl methyl cellulose. The preferred absorbent aid is DL malic acid. The medicine is dissolved in organic solvents. The preferred organic solvents are ethanol and methylene chloride. The protective layer contains polyethylene glycol (PEG) 20,000, which is applied on the medicine emulsion layer.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A method for determining the hydration status of a person prompts the person to breathe while in a first postural position during which the method measures a first heart rate variability (HRV) value. The person is prompted to change to a second postural position, and the method measures a second HRV value. A difference between the first HRV value and the second HRV value is a daily score. The daily score is subtracted from a baseline to obtain a hydration score. In certain embodiments, the person is requested to respond to a plurality of subjective questions. The method processes the subjective responses and the daily score to determine whether the person is adequately hydrated. In certain embodiments of the method, the person is requested to identify the color of the person&#39;s urine. The identified color is processed with the daily score and the subjective responses to determine hydration.
PROBLEM TO BE SOLVED: To obtain an oral cavity composition having improved application feeling, exactly screening the strange taste due to sodium hydrogen carbonate by formulating one or two kinds of specific compounds to a composition for oral cavity containing sodium hydrogen carbonate. SOLUTION: A combination of a salt of glycyrrhizic acid with 1,8-cineole are formulated to an oral cavity composition containing &gt;=5wt.% of sodium hydrogen carbonate. These glycyrrhizic acid salt and 1,8cineole synerigistically act to screen the strange taste of sodium hydrogen carbonate. The glycyrrhizic acid salt is, for example, monoammonium glycyrrhizate or the like and its amount in the formulation is about 0.005-0.5wt.%. The 1,8-cineole is used as a perfume and the essential oil containing this compound may be used as it is and its amount in the formulation is at a level of 0.001-0.5wt.%. This composition may be prepared to mouth wash, chewing gum and the like.
PURPOSE:To obtain the reagent, which can perform the quick, highly reliable identification without complicated procedures by chemically bonding radioactive material, fluorescence pigment, enzyme a marker for observation with an electron microscope or a group containing the structure for bonding them at the secondary step to an IgG antibodies. CONSTITUTION:Radiation active material, fluorescence pigment, enzyme a marker for observation with an electron microscope or a group containing the structure for bonding these materials in the second step are chemically bonded to IgG antibodies. The IgG antibodies are secreted from hybridoma between the antibody producing cells of anti-human prostate cancer and cells which can be subcultured for a long period in vitro. Thus, the derivative of the IgG antibodies is obtained. The derivative is contained, and the reagent for identification is obtained. The radioactive material is &lt;125&gt;I, the fluorescence pigment is fluorescein or rhodamine and the enzyme is peroxidase or rhodamine. The structure for bonding the radiation active material, the fluorescence pigment, the enzyme or the marker for observation with the electron microscope in the second step is biotin.
PURPOSE:An antacid, prepared by dispersing an inorganic antacid in a water absorbing swellable high polymer, capable of rapidly increasing the pH in the stomach after the administration thereof, having the prolonged action and protective action on the mucous membranes of the stomach and ulcerous surfaces, etc., and capable of continuous administration to the ulcerous surfaces loaded with a chemical. CONSTITUTION:An antacid prepared by dispersing an inorganic antacid in a water absorbing swellable high polymer, preferably a high polymer obtained by gelatinizing a water-soluble high polymer by crosslinking thereof. In use, the antacid is prepared in the form of a granules or particles, and incorporated with a medicine for the stomach and bowels, internal prolonged release pharmaceutical, etc. A natural high polymer, e.g. gelatin, agar, KONJAK powder, (devil&#39;s-tongue powder), etc. may be preferably used as the raw material for the water absorbing and swellable high polymer. Sodium bicarbonate, etc. is used as the inorganic antacid in the form of granules or particles. The size thereof is preferably 200 mesh or finer. The amount of the inorganic antacid is preferably 10-400pts.wt. based on 100pts.wt. water absorbing and swellable high polymer.
PURPOSE:To provide the wound coating material which exhibits an antimicrobial property even without releasing drugs and has a detoxication power to a bacterial toxin by immobilizing polypeptide antibiotics by cavalent bonding to the surfaces of fibers constituting cloth. CONSTITUTION:A polypeptide-based antibiotic is immobilized by covalent bonding to the surfaces of the fibers constituting cloth of a wound coating material. The ratio of the extension rate in the biaxial directions orthogonal to each other of the cloth surface is specified to &gt;=50%. The cloth is formed of a knitted fabric cross knitted of blended fiber consisting of plural blank materials, combined filament yarns and/or plural fibers. As a result, the treatment of the wound is possible without allowing the intrusion of antibiotic into the body through the wound part, and therefore, side effects are prevented. Since an infection prevented, the treatment environment of the wound is improved and further the microbial cell toxin is adsorbed, and therefore an inflammation reaction is suppressed and healing is accelerated.
PURPOSE:To isolate a pure saponin mixture containing a novel saponin useful for preventing and treating arteriosclerosis, by concentrating an extract solution of Astragali Radix with a lower alcohol and treating the resultant extract by a special method. CONSTITUTION:Astragali Radix is first extracted with a lower alcohol preferably while warming or heating, and the resultant extract solution is concentrated and dissolved in a lower alcohol to give a solution, which is treated with an adsorbent, e.g. silicon gel. A fraction eluted from the above-mentioned adsorbent is subsequently subjected to chromatography, e.g. reversed phase silica gel chromatography, to isolate a saponin mixture. The above-mentioned mixture contains 10 or more novel compounds consisting of a compound expressed by formula I (R&lt;2&gt; is beta-D-glucopyranosyl, and R&lt;3&gt; is 2,3,4-tri-O-acetyl-beta- D-xylopyranosyl when R&lt;1&gt; is H) and a compound expressed by formula II.
A plaster for treating hyperosteogeny bony spurs comprises Bunge Corydalis Herb, Seed of Garden Balsam, root of Nutgall Tree, Boswellia carteri, myrrh, Bark of Girald Daphne, Aconitum kusnezoffii, Japan Buttercup, Hindu Datura seed, mirabilite, Spina Gleditsiae, minium, Herba Speranskiae Tuberculatae, willow fungus and Gloeostereum incarnatum. A production method of the plaster comprises the following steps: boiling Bunge Corydalis Herb in water, filtering the obtained decoction, concentrating the filtered decoction through sequentially using strong fire and weak fire, adding medicinal powders formed by grinding remaining medicines when the obtained concentrate is clear and dilute and forms a fine line when being picked by chopsticks, and uniformly stirring. The production method solves the problem of destroy of too high temperature of oil frying to effective components in the traditional Chinese medicines), and can treat hyperosteogeny. The plaster is convenient for people to use, realizes health and no flowing, reduces patients&#39; pains, and reduces the economy burden. Hyperosteogeny is treated by dispelling wind and cold, eliminating dampness and warming yang according to arthralgia in the traditional Chinese medicine field. Chinese medicine science and western medicine science are combined in the invention, and the causing reasons of hyperosteogeny, considered in the invention, are calcium deficiency, kidney vacuity and bone heat, so the hyperosteogeny is treated in the invention through combining supplementation and draining, clearing heat and reducing phlegm, softening hardness and detoxifying, reducing maxillary osteomyelitis fatigue, and strengthening bones and relieving exterior syndromes.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an oral composition having excellent sense of use and moisture-retaining effects.  &lt;P&gt;SOLUTION: The oral composition contains an extract of humic soil. The extract of the humic soil is obtained by carrying out the extraction by adding water to the humic soil, filtering the obtained extract by using a filter of 0.1-0.2 μm, and purifying the obtained filtrate. The oral composition is free from an antiseptic agent. The oral composition contains cetylpyridium chloride besides them.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
This invention relates to &#34;targeted&#34; viral or non-viral vector particles, including retroviral vector particles, adenoviral vector particles, adeno-associated virus vector particles, Herpes Virus vector particles, and pseudotyped viruses, and to non-viral vectors that contain a viral protein as part of a virosome or other proteoliposomal gene transfer vector. More particularly, this invention relates to viral and non-viral vector particles, including retroviral vector particles, adenoviral vector particles, adeno-associated virus vector particles, Herpes Virus vector particles, pseudotyped viruses, and non-viral vectors having a modified, or chimeric viral surface protein, such as, for example, a chimeric viral envelope polypeptide, wherein such modified viral surface protein, such as a modified viral envelope polypeptide, includes a peptide which is a tumor vasculature targeting motif or TVTM. The TVTM peptide may be placed between two consecutive amino acid residues of the viral surface protein, or may replace amino acid residues which have been removed from the viral surface protein. The term &#34;polypeptide&#34; as used herein means a polymer of amino acids and does not refer to any particular length of polymer. Such term also includes post-translationally modified polypeptides or proteins (e.g., glycosylated, acetylated, phosphorylated, etc.).